Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Eli Lilly and Company is conducting a Phase 3b study titled A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Retatrutide Treatment in the Maintenance of Weight Reduction in Individuals With Obesity. The study aims to assess the effectiveness of retatrutide in maintaining weight loss among individuals with obesity, highlighting its significance in addressing a prevalent health issue.
The intervention being tested is retatrutide, a drug administered subcutaneously, designed to help maintain weight loss. The study involves two phases: an initial 80-week phase where all participants receive retatrutide, followed by a 36-week phase where participants are randomized to continue with retatrutide or switch to a placebo.
The study employs a randomized, double-blind, placebo-controlled design with a parallel intervention model. Both participants and investigators are masked to the treatment allocation, ensuring unbiased results. The primary purpose is to evaluate the treatment’s efficacy in sustaining weight reduction.
The study began on February 28, 2025, with primary completion expected around 125 weeks later. The latest update was submitted on August 26, 2025, indicating ongoing recruitment and progress.
This study update has potential implications for Eli Lilly’s stock performance and investor sentiment, as successful results could enhance the company’s position in the obesity treatment market. Competitors in the weight management sector will likely monitor these developments closely.
The study is ongoing, with further details available on the ClinicalTrials portal.